Equities

Indivior PLC

INDV:LSE

Indivior PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,463.00
  • Today's Change55.00 / 3.91%
  • Shares traded544.64k
  • 1 Year change-4.13%
  • Beta-0.2605
Data delayed at least 20 minutes, as of Apr 29 2024 15:36 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Indivior PLC grew revenues 21.31% from 901.00m to 1.09bn. In addition the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as a percent of sales). The company reported positive net income, improving from a loss of 53.00m to a profit of 2.00m.
Gross margin82.83%
Net profit margin0.44%
Operating margin0.36%
Return on assets0.31%
Return on equity12.20%
Return on investment0.77%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Indivior PLC fell by 458.00m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 315.00m for operations while cash used for investing totalled 98.00m.
Cash flow per share0.1784
Price/Cash flow per share74.58
Book value per share0.0589
Tangible book value per share-1.30
More ▼

Balance sheet in USDView more

Indivior PLC has a Debt to Total Capital ratio of 96.54%, a lower figure than the previous year's 372.22%.
Current ratio0.9245
Quick ratio0.7352
Total debt/total equity27.90
Total debt/total capital0.9654
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 96.08%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		95.17
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.